Fundraising

Sareum Holdings PLC
22 October 2007


For immediate release                                            22 October 2007





                              SAREUM HOLDINGS PLC

                          ("Sareum" or "the Company")

                                  Fundraising

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce that it has agreed to place 138,888,889
Ordinary Shares of 0.025p nominal value at a price of 0.9p per share to raise
£1.25 million before expenses. 25,944,889 of these shares are being placed
subject to approval at the Company's AGM on 15 November 2007.

Mr and Mrs Leonard Licht have agreed to subscribe to 33,333,333 new Ordinary
Shares and together will hold 13.43% of the Company's enlarged issued share
capital1. The Directors of the Company have agreed to subscribe to 2,000,000 new
Ordinary Shares. The remainder is being placed with clients of the Company's
broker, Ellis Stockbrokers Limited.

Mr Leonard Licht is a Partner of Hg Capital and previously has been a former
founding director and Vice Chairman of Mercury Asset Management and the Deputy
Chairman of Jupiter Tyndall Group.

The funds raised from this share issue will used to advance the Company's
in-house development pipeline of cancer drug candidates and to provide
additional working capital.

The Directors share purchases are:
Name                               Number of shares       Number of shares held   Percentage of issued
                                          purchased    following share purchase         share capital1
Dr Paul Harper                            1,111,111                   2,444,444                  0.41%
Dr Tim Mitchell                             111,111                  42,780,471                  7.15%
Mr Giorgio Reggiani                         555,556                     555,556                  0.09%
Dr John Reader                              111,111                  43,447,111                  7.26%
Dr David Williams                            66,667                  42,735,987                  7.14%

Application has been made for the admission of 112,944,000 shares to trading on
AIM with admission expected to take place on 26 October 2007. Application will
be made for the admission of 25,944,889 shares to trading on AIM with admission
expected to take place on 21 November 2007.

1 Percentage of share capital assuming AGM approval for the issue of 25,944,889
new Ordinary Shares.

Commenting on the announcement, Sareum's Chief Executive Officer, Dr Tim
Mitchell said: "This placing will provide valuable funds to advance our in-house
cancer programs towards a stage where they become attractive licencing
opportunities. We are also very pleased that Mr and Mrs Licht have chosen to
increase their shareholding in Sareum."



For further information:


Sareum Holdings plc                                               01223 497700

Tim Mitchell, Chief Executive Officer
Buchanan Communications                                          020 7466 5000

Tim Anderson, Mary-Jane Johnson
Grant Thornton Corporate Finance                                 020 7383 5100

Philip Secrett, Colin Aaronson


Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR.  For further information, please visit
www.sareum.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange